Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PFIZER, INC.

(PFE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Pfizer : Moderna expanding kids vaccine study to better assess safety

07/26/2021 | 04:53pm EDT

WASHINGTON (AP) — Moderna said Monday it plans to expand the size of its COVID-19 vaccine study in younger children to better detect rare side effects, such as a type of heart inflammation recently flagged by U.S. health authorities.

The company said it is in talks with the Food and Drug Administration to enroll more study participants under age 12. It had intended to test the vaccine in about 7,000 children, with some as young as 6 months. The Cambridge, Massachusetts-based company said via email it hasn't decided on how many kids might be added.

The announcement comes as U.S. COVID-19 cases are rising and schools prepare to welcome students back to classrooms. At the same time, regulators continue to review cases of a rare type of heart inflammation called myocarditis that has been reported in a small number of teenagers who got the Moderna or Pfizer shots.

Pfizer said on Monday that if it makes changes to its vaccine testing in children, it will provide an update then. The New York-based company is testing its vaccine in up to 4,500 children in the United States and Europe.

The FDA said in a statement it could not comment on its discussions with companies, but added “we do generally work with sponsors to ensure the number of participants in clinical trials are of adequate size to detect safety signals.”

The news was first reported by the New York Times.

U.S. officials and independent medical experts said last month the benefits of the vaccines far outweigh the risks of the side effect, which has been reported in several hundred people younger than 30. But any vaccine safety issues could slow uptake, particularly among parents wary of taking any health risk with their children.

Currently, Pfizer has the only U.S. vaccine authorized for children 12 years and up, while Moderna is expecting an FDA ruling on its application in the coming days.

While teens receive the same dose as adults, younger children may need smaller doses. That additional complexity adds time to drugmakers’ research and application timelines.

Moderna said Monday it expects to have enough data to apply for FDA authorization in younger kids by late this year or early 2022.

Pfizer has previously said it expects to apply in September for children ages 5 through 11. Results for two younger age groups that began testing a little later should be available by October or November, according to the company.

Johnson reported from Fairless Hills, Pennsylvania.

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

Copyright 2021 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission., source Associated Press News

Stocks mentioned in the article
ChangeLast1st jan.
MODERNA, INC. 1.28% 439.38 Delayed Quote.315.47%
PFIZER, INC. 0.74% 44.25 Delayed Quote.20.08%
All news about PFIZER, INC.
12:55pPFIZER : BioNTech To See Increased COVID-19 Purchase As US Plans To Boost Global Donations..
MT
11:35aPFIZER : Biden doubles US global donation of COVID-19 vaccine shots
AQ
10:46aZenith Epigenetics and Newsoara Announce Initiation of a Randomized Phase 2b Metastatic..
AQ
10:43aPFIZER : CDC panel tackles who needs booster shot of COVID vaccine
AQ
09:42aWALL STREET STOCK EXCHANGE : Fed verdict is imminent
09:02aPFIZER : U.S. to double global shipments of COVID-19 vaccine doses to over 1 billion
AQ
08:36aPFIZER : Biden to double US global donation of COVID-19 vaccine shots
AQ
08:29aWHITE HOUSE REPORTEDLY URGED PFIZER : NY Times
MT
07:20aPFIZER : COVID-19 Vaccine Elicits Strong Immune Response As Second Dose, Thailand Study Sa..
MT
06:54aPFIZER : BioNTech to Expand Agreement With US Government to Supply COVID-19 Vaccine Doses ..
MT
More news
Analyst Recommendations on PFIZER, INC.
More recommendations
Financials (USD)
Sales 2021 81 111 M - -
Net income 2021 18 438 M - -
Net Debt 2021 28 980 M - -
P/E ratio 2021 13,0x
Yield 2021 3,59%
Capitalization 246 B 246 B -
EV / Sales 2021 3,39x
EV / Sales 2022 4,01x
Nbr of Employees 78 500
Free-Float 59,3%
Chart PFIZER, INC.
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | PFE | US7170811035 | MarketScreener
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 20
Last Close Price 43,92 $
Average target price 45,08 $
Spread / Average Target 2,64%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
Frank A. D'Amelio Chief Financial Officer & EVP-Global Supply
Mikael Dolsten Chief Scientific Officer & Research President
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Aida Habtezion Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER, INC.20.08%246 246
JOHNSON & JOHNSON4.54%433 122
ROCHE HOLDING AG9.82%321 584
NOVO NORDISK A/S52.07%234 070
ELI LILLY AND COMPANY36.32%208 668
ABBVIE INC.0.00%189 353